0000000000241861

AUTHOR

Christophe Louvet

showing 5 related works from this author

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multice…

2020

Half of patients newly diagnosed with esophageal squamous cell cancer (ESCC) have metastatic disease (mESCC) and therefore a poor prognosis. Furthermore, half of patients with initial loco-regional disease present disease recurrence after surgery and/or chemoradiation. In mESCC, the recommended first-line treatment combines 5-fluorouracil and cisplatin, although this has not been validated by a phase III trial. Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy. Several molecules have been evaluated in phase I/II trials or retrospective studies (docetaxel, paclitaxel and irinotecan) but…

Oncologymedicine.medical_specialtyEsophageal NeoplasmsPaclitaxel[SDV]Life Sciences [q-bio]medicine.medical_treatmentEsophageal cancerPhases of clinical researchIrinotecan03 medical and health scienceschemistry.chemical_compoundClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopicComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyCisplatin0303 health sciencesChemotherapyHepatologyPerformance statusbusiness.industryGastroenterologyEsophageal cancermedicine.disease3. Good healthSurvival RateIrinotecanPaclitaxelchemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionQuality of LifeSquamous cell cancerEsophageal Squamous Cell CarcinomaFluorouracilFranceNeoplasm Recurrence Localbusinessmedicine.drugDigestive and Liver Disease
researchProduct

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastri…

2021

International audience; Gastric or gastro-oesophageal junction (GEJ) adenocarcinomas present poor overall survival (OS). First-line chemotherapy regimen for patients with HER2-negative tumours is based on a doublet or triplet of fluoropyrimidine plus platinum salt ± taxane. Second-line chemotherapy (Docetaxel or Irinotecan) improves OS which nonetheless remains poor (around 5 months). The first results of immune checkpoint inhibitors (anti-PD-1) combined with chemotherapy in metastatic gastric and GEJ cancers were discordant in recent phase III trials. Data on dual-blockade (anti-PD-L1 or anti-PD-1 plus anti-CTLA-4) plus chemotherapy are lacking. DURIGAST is a randomised, multicenter, non-c…

OncologyMalemedicine.medical_specialtyDurvalumabEsophageal NeoplasmsLeucovorinPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaAntibodies Monoclonal Humanized03 medical and health sciencesImmune checkpoint inhibitors0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyTaxaneHepatologybusiness.industryGastroenterologyAntibodies Monoclonal[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyChemotherapy regimen[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology3. Good healthIrinotecanTreatment OutcomeDocetaxel030220 oncology & carcinogenesisFOLFIRI030211 gastroenterology & hepatologyCamptothecinFemaleEsophagogastric JunctionFluorouracilFrancebusinessGastric cancerTremelimumabmedicine.drug
researchProduct

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treat…

2020

Background Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for COVID-19 severity and mortality in cancer patients were investigated. Patients and Methods In this large nationwide retro-prospective cohort study, we collected data on patients with solid tumours and COVID-19 diagnosed between March 1 and June 11, 2020. The primary endpoint was all-cause mortality and COVID-19 severity, defined as admission to an intensive care unit (ICU) and/or mechanical ventilation and/or death, was one of the secondary endpoints. Results From April 4 to June 11, 2020, 1289…

Male0301 basic medicineCancer Researchmedicine.medical_treatmentDiseaselaw.inventionCohort Studies0302 clinical medicineMechanical ventilationRisk FactorslawNeoplasmsMedicineProspective StudiesProspective cohort studyOriginal ResearchCancerIntensive care unit3. Good healthDeathOncology030220 oncology & carcinogenesisFemaleFranceImmunotherapyCohort studymedicine.medical_specialtychemotherapy. radiotherapyAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineHumansChemotherapyIntensive care unitMortalityPandemicsAgedRetrospective StudiesChemotherapyRadiotherapySARS-CoV-2business.industryCancerCOVID-19Retrospective cohort studyOdds ratiomedicine.diseaseAged; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; COVID-19/mortality; Cohort Studies; Female; France/epidemiology; Humans; Male; Neoplasms/mortality; Neoplasms/therapy; Neoplasms/virology; Pandemics; Prospective Studies; Retrospective Studies; Risk Factors; SARS-CoV-2/isolation & purification; COVID-19; Cancer; Chemotherapy; Death; Immunotherapy; Intensive care unit; Mechanical ventilation; Mortality; Radiotherapy030104 developmental biologybusiness
researchProduct

Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis

2011

Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110ΔE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorou…

Organoplatinum CompoundsColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Blotting WesternFluorescent Antibody TechniqueAntineoplastic AgentsBiologyBioinformaticsReal-Time Polymerase Chain ReactionTransfectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineHeat shock proteinCell Line TumormedicineHumansImmunoprecipitationHSP110 Heat-Shock ProteinsneoplasmsCellular localizationComputingMilieux_MISCELLANEOUS030304 developmental biologyDNA Primers0303 health sciencesChemotherapyMicrosatellite instabilityGeneral MedicineTransfectionmedicine.diseasePrognosisdigestive system diseases3. Good healthOxaliplatinOxaliplatin030220 oncology & carcinogenesisCancer cellMutationCancer researchRegression AnalysisMicrosatellite InstabilityFluorouracilColorectal Neoplasmsmedicine.drugPlasmids
researchProduct

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation …

2015

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/…

AdultMaleProto-Oncogene Proteins B-rafOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinGlutamic AcidKaplan-Meier EstimateDNA Mismatch RepairDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineHumansStage (cooking)Infusions IntravenouseducationAgedNeoplasm Stagingeducation.field_of_studyChemotherapybusiness.industryHazard ratioValineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFluorouracilColonic NeoplasmsInjections IntravenousMutationFemaleFluorouracilbusinessAdjuvantFollow-Up Studiesmedicine.drugJournal of Clinical Oncology
researchProduct